{
    "nct_id": "NCT03682796",
    "official_title": "Phase 1, Multicenter, Open-Label Study of the Antibody-Drug Conjugate TRPH-222 in Subjects With Relapsed and/or Refractory B-Cell Lymphoma",
    "inclusion_criteria": "Inclusion Criteria\n\n* Age â‰¥ 18 years at the time of signing the informed consent\n* Histologically confirmed (2016 WHO lymphoma classification) B-cell NHL that is DLBCL, FL (including transformed FL), MZL, or MCL\n* Relapsed and/or refractory NHL requiring systemic therapy and have failed, are intolerant to, or are considered ineligible for standard of care anticancer treatments that are known to be potentially curative. Subjects must not be current candidates for HSCT. Participants who refuse standard treatments may also be considered provided that documentation is provided that the subject has been made aware of all therapeutic options\n* Eastern Cooperative Oncology Group (ECOG) status 0-2\n\nExclusion Criteria\n\n* Presence of a leukemic phase of the lymphoma\n* \"Double hit\" or \"triple hit\" germinal center B cell lymphoma\n* Previous solid organ allograft (except for corneal transplant)\n* Peripheral neuropathy > NCI-CTCAE Grade 1\n* Significant organ dysfunction that would preclude study participation\n* Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias\n* Any other serious active disease or co-morbid medical condition, according to the Investigator's decision or Medical Monitor, that will substantially increase the risk associated with the subject's participation in the study\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}